The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Bladder Cancer MORE >>

Bempegaldesleukin, a novel interleukin-2 therapy, showed promising activity when combined with nivolumab in patients with metastatic urothelial carcinoma who were cisplatin ineligible or refused standard therapy, according to preliminary data from the PIVOT-02 study.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.